Market capitalization | $29.25b |
Enterprise Value | $34.19b |
P/E (TTM) P/E ratio | 25.29 |
EV/FCF (TTM) EV/FCF | 21.85 |
EV/Sales (TTM) EV/Sales | 3.68 |
P/S ratio (TTM) P/S ratio | 3.15 |
P/B ratio (TTM) P/B ratio | 1.84 |
Revenue growth (TTM) Revenue growth | -1.91% |
Revenue (TTM) Revenue | $9.29b |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
35 Analysts have issued a Biogen forecast:
35 Analysts have issued a Biogen forecast:
Jun '24 |
+/-
%
|
||
Revenue | 9,288 9,288 |
2%
2%
|
|
Gross Profit | 6,350 6,350 |
4%
4%
|
|
EBITDA | 2,385 2,385 |
14%
14%
|
EBIT (Operating Income) EBIT | 1,813 1,813 |
17%
17%
|
Net Profit | 1,159 1,159 |
57%
57%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Christopher Viehbacher |
Employees | 7,570 |
Founded | 1978 |
Website | www.biogen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.